Cadex Genomics is focused on enhancing the treatment and monitoring of cancer patients, particularly those with stage IV solid tumors. Their flagship product, Alibrex®, is a blood-based assay designed to provide real-time therapy monitoring. Unlike traditional methods that can take up to three months to assess treatment efficacy, Alibrex enables oncologists to evaluate a patient's response to therapy within just 12 days. This rapid feedback mechanism allows for timely adjustments in treatment, reducing the risk of patients undergoing ineffective therapies and minimizing associated toxicity and costs. The technology leverages the detection of circulating tumor DNA (ctDNA) in the bloodstream, comparing pre-treatment and post-treatment DNA concentrations to determine whether a tumor is responding to therapy.

The efficacy of Alibrex has been supported by various clinical studies, demonstrating its ability to distinguish between cancerous and non-cancerous DNA fragments with high accuracy. For instance, a proof-of-concept study showed an impressive area under the curve (AUC) of 0.989, indicating strong performance in identifying disease progression. Further studies, including a multi-site trial involving patients with colorectal, breast, and lung cancers, confirmed Alibrex's predictive capabilities, achieving a positive predictive value (PPV) of 100% and a negative predictive value (NPV) of 91%. These results underscore the potential of Alibrex to transform cancer treatment by facilitating personalized and timely therapeutic decisions based on individual tumor biology.

United States

Cadex Genomics develops molecular diagnostic tests to guide cancer treatment using liquid-based technology to provide personalized insight into the therapy response. By combining proven approaches to measuring DNA with cutting-edge technology to improve accuracy and sensitivity Cadex Genomics provides unique insight into therapy response using simple blood draws.

Alibrex is a blood-based assay, developed to help physicians identify patients who are not responding to drug therapy. The test is optimized to maximize NPV, that is, minimize the number of false non-responders.

Cadex Genomics

Company Details